Lenalidomide proved effective in multisystem Langerhans cell histiocytosis

SZTURZ, Petr; Zdeněk ADAM; Zdeněk ŘEHÁK; Renata KOUKALOVÁ; Radka ŠLAISOVÁ; Olga STEHLÍKOVÁ; Jana CHOVANCOVÁ; Martin KLABUSAY; Marta KREJČÍ; Luděk POUR; Roman HÁJEK and Jiří MAYER. Lenalidomide proved effective in multisystem Langerhans cell histiocytosis. Acta Oncologica. 2012, vol. 51, No 3, p. 412-415. ISSN 0284-186X. Available from: https://dx.doi.org/10.3109/0284186X.2011.631581.

Basic information

Original name

Lenalidomide proved effective in multisystem Langerhans cell histiocytosis

Authors

SZTURZ, Petr (203 Czech Republic, guarantor, belonging to the institution); Zdeněk ADAM (203 Czech Republic, belonging to the institution); Zdeněk ŘEHÁK (203 Czech Republic); Renata KOUKALOVÁ (203 Czech Republic); Radka ŠLAISOVÁ (203 Czech Republic, belonging to the institution); Olga STEHLÍKOVÁ (203 Czech Republic, belonging to the institution); Jana CHOVANCOVÁ (203 Czech Republic); Martin KLABUSAY (203 Czech Republic, belonging to the institution); Marta KREJČÍ (203 Czech Republic, belonging to the institution); Luděk POUR (203 Czech Republic, belonging to the institution); Roman HÁJEK (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution)

Edition

Acta Oncologica, 2012, 0284-186X

---

Other information

Language

English

Type of outcome

Article in a journal

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Norway

Confidentiality degree

is not subject to a state or trade secret

Impact factor

Impact factor: 2.867

RIV identification code

RIV/00216224:14110/12:00059809

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3109/0284186X.2011.631581

UT WoS

000302731800022

Keywords in English

Langerhans cell histiocytosis; lenalidomide; PET/CT

Tags

International impact

---

Abstract

V originále

Langerhans cell histiocytosis (LCH) is a rare idiopathic disease with diverse clinical manifestations ranging from a single osteolytic lesion to generalized disease. Various treatment regimens have been proposed for the multisystem type, however, with inconsistent outcomes. Herein we are the first to report on a therapy effect of a lenalidomide-based regimen in a patient with repeatedly relapsed aggressive form of multisystem LCH.

---

Links

LC06027, research and development project	Name: Univerzitní výzkumné centrum - Česká myelomová skupina (Acronym: LC MGUS) Investor: Ministry of Education, Youth and Sports of the CR, University Research Centre - Czech Myeloma Group
MSM0021622434, plan (intention)	Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
NS9671, research and development project	Name: Stanovení hladiny cytokinů a kostimulačních molekul v plasmě, kostní dřeni, leukocytech a nádorových buňkách nemocných s hematologickými malignitami a jejich vztah k aktivitě nemoci, transplantaci krvetvorby, rozvoji komplikací (GvHD) a riziku relapsu. Investor: Ministry of Health of the CR
NT11154, research and development project	Name: Úloha mitotické disrupce v B lymfocytech u mnohočetném myelomu Investor: Ministry of Health of the CR